Physician profile
Mitchell R Camp
NPI 1942694328
$4,439.79
in general payments reported to CMS, 2019-2025
30 companies · $448 in 2025
The $448 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $171 · 2021: $372 · 2022: $917 · 2023: $1,027 · 2024: $1,058 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $666.76 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $631.50 | 2022-2025 | Qelbree, Qelbree |
| Pfizer INC. | $398.43 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $379.38 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $362.55 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Kaleo, INC. | $262.85 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $248.45 | 2019-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $203.31 | 2019-2023 | |
| Cranial Technologies, INC | $190.37 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $158.19 | 2020-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Seqirus USA INC | $125.90 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $121.28 | 2019-2025 | Bexsero |
| Astrazeneca Pharmaceuticals LP | $99.06 | 2023-2024 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $92.84 | 2019-2021 | |
| Genentech USA, INC. | $76.11 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $63.33 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $53.80 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $43.93 | 2019-2021 | |
| Cognoa, INC. | $37.71 | 2022 | |
| Exeltis, USA INC. | $29.41 | 2023 | Slynd |
| Vertical Pharmaceuticals, LLC | $28.30 | 2025 | Relexxii |
| Amneal Pharmaceuticals LLC | $26.43 | 2019 | |
| Hologic Sales and Service, LLC | $22.22 | 2019 | |
| Lnhc, INC | $21.50 | 2025 | Zelsuvmi |
| Biomarin Pharmaceutical INC. | $19.50 | 2025 | Voxzogo 1.2mg |
| Kowa Pharmaceuticals America, INC. | $16.68 | 2024 | Zoryve |
| Nestle Healthcare Nutrition INC. | $15.93 | 2023 | |
| Adlon Therapeutics L.P. | $15.74 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.33 | 2025 | Neffy |
| Qiagen, LLC | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Camp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.